REG - Abingdon Health PLC - c. US$2.5m companion diagnostic test contract win

Abingdon HealthAnnouncement

Thu 07:01

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250731:nRSe2883Ta&default-theme=true

RNS Number : 2883T  Abingdon Health PLC  31 July 2025

 

This announcement contains inside information for the purposes of Article 7 of
the UK version of Regulation (EU) No 596/2014 which is part of UK law by
virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the
publication of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public domain.

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

c. US$2.5m companion diagnostic test contract win

 

Full CDMO service contract for development, scale-up, technical transfer,
manufacture and full regulatory support

 

York, U.K.  31 July 2025: Abingdon Health plc (AIM: ABDX), a leading
international developer, manufacturer and distributor of high quality and
effective rapid tests, announces a new contract win with an expected value of
c. US$2.5 million.

 

The Company has signed a Master Service Agreement ("MSA") with a leading
global pharmaceutical company for the development and regulatory approval of a
companion diagnostic lateral flow point of care test. The MSA covers the
feasibility, optimisation, scale-up, technical transfer and manufacturing of
the completed product alongside comprehensive regulatory support. The project
is expected to take approximately 24 months via works orders under the MSA
which are expected to total c. US$2.5 million.

 

This contract win underlines the strength of Abingdon Health's CDMO offering
which provides customers with comprehensive support to take an "idea through
to commercial success".  The recent acquisitions of IVDeology and CS
Lifesciences, combined with the launch of the Abingdon Analytical Ltd
performance evaluation laboratory, has allowed Abingdon to complement its
existing lateral flow development and manufacturing capabilities with a full
quality and regulatory service offering supported by its 45-strong regulatory
team. The significant benefits of having one outsourced partner covering all
aspects of product development is resonating well with customers as evidenced
by this new contract win.

 

Abingdon Health's brochure
(https://www.abingdonhealth.com/wp-content/uploads/2025/06/Abingdon-Health-Group-Leaflet-JUN2025.pdf)
outlines the comprehensive support the Group can now provide to its
international customers.

 

Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented: "This
contract award demonstrates the value of our comprehensive CDMO platform. We
deliver end-to-end diagnostic solutions from initial concept through to market
launch, and this win reflects strong customer confidence in our integrated
approach. Our companion diagnostics expertise has become a key competitive
advantage, particularly our ability to coordinate both diagnostic and the
client's therapeutic development pathways. This expertise, combined with our
regulatory knowledge, provides clients with seamless project management and
reduced complexity."

 

Enquiries:

 

 Abingdon Health plc                           www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Hand, Executive Chairman                                            Via Walbrook PR

 Tom Hayes, CFO

 Zeus (Sole Broker and Nominated Adviser)                                    Tel: +44 (0)20 3829 5000
 Antonio Bossi / Jacob Walker (Corporate Finance)
 Fraser Marshall (Corporate Broking)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About Abingdon Health plc

Abingdon Health Group is a leading med-tech contract service provider
offering its services to an international customer base.

 

The Company's CDMO division
(https://urldefense.proofpoint.com/v2/url?u=https-3A__www.abingdonhealth.com_services_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=HA76POaNPDBWSuSNqpvm6h6sTVAmwDfGPxyLLvvNBHg&e=)
 offers lateral flow product development, regulatory support, technology
transfer and manufacturing services for customers looking to develop new
assays or transfer existing laboratory-based assays to a lateral flow
format. Abingdon Health's CDMO division has the internal capabilities to
take lateral flow projects, in areas such as infectious disease and clinical
testing, including companion diagnostics, animal health and environmental
testing, from initial concept through to routine and large-scale
manufacturing; from "idea to commercial success".

 

Abingdon's regulatory services companies, Compliance Solutions (Life
Sciences)
(https://urldefense.proofpoint.com/v2/url?u=https-3A__cslifesciences.com&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=PvbE1xuJgNrAaK0I9QSrYjO3acai4ITHsbheoH-Cavc&e=)
 and IVDeology
(https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ivdeology.co.uk&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=mbRruUP_NEre93fFYpNkBweGVcmSCnXpjUyMQmUx1yI&e=)
, provide a broad range of regulatory services to the in vitro diagnostic and
wider medical device industry, to support customers in bringing products to
market across a range of territories including the USA, EU and the UK. Our
consultancy services range from design, implementation and maintenance of
quality management systems, preparation of technical files for regulatory
approvals, part-time and interim management support, auditing both internal
and external, management reviews and presentations, training and mentoring.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonsimplytest.com&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=71SLyhJsm1hJqJvXuK0jPc4-fr_IZIW_VOOfo4sJwQw&e=)
 e-commerce site offers consumers a range of information to support them in
making informed decisions on the tests available. In addition, the site
provides Abingdon's contract services customers with a potential route to
market for self-tests. The Abingdon Simply Test range is also sold through
international distributors and through other channels in
the UK and Ireland, such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonhealth.com_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=Cd1Yy0EoU5vx33xedoTE3bCKbljgDOIRD8ol-bb59BM&e=)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTWPUMGMUPAPGU